Cited by 182Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Treatment

The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice

Open access
Russo, Roberto, LoVerme, Jesse, La Rana, Giovanna, Compton, Timothy R., Parrott, Jeff, Duranti, Andrea, Tontini, Andrea, Mor, Marco +3 more·2007·The Journal of Pharmacology and Experimental Therapeutics

Abstract

Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase that catalyzes the cleavage of bioactive fatty acid ethanolamides, such as the endogenous cannabinoid agonist anandamide. Genetic deletion of the faah gene in mice elevates brain anandamide levels and amplifies the antinociceptive effects of this compound. Likewise, pharmacological blockade of FAAH activity reduces nocifensive behavior in animal models of acute and inflammatory pain. In the present study, we investigated the effects of the selective FAAH inhibitor URB597 (KDS-4103, cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) in the mouse chronic constriction injury (CCI) model of neuropathic pain. Oral administration of URB597 (1-50 mg/kg, once daily) for 4 days produced a dose-dependent reduction in nocifensive responses to thermal and mechanical stimuli, which was prevented by a single i.p. administration of the cannabinoid CB(1) receptor antagonist rimonabant (1 mg/kg). The antihyperalgesic effects of URB597 were accompanied by a reduction in plasma extravasation induced by CCI, which was prevented by rimonabant (1 mg/kg i.p.) and attenuated by the CB(2) antagonist SR144528 (1 mg/kg i.p.). Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content. The results provide new evidence for a role of the endocannabinoid system in pain modulation and reinforce the proposed role of FAAH as a target for analgesic drug development.

Integrity signals

Registry

Crossref · 10.1124/jpet.107.119941

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In CCI rats, chronic administration of either AM404 or URB597 suppresses plasma extravasation, a condition associated with neuropeptide release at peripheral levels.

    “In CCI rats, chronic administration of either AM404 or URB597 suppresses plasma extravasation, a condition associated with neuropeptide release at peripheral levels.54, 55”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Russo, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., & Piomelli, D.
Affiliations
University of Naples Federico II (IT)
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2007-07
Volume
322
Issue
1
Pages
236-242
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2105546002
Cited by
182
References
40
Citations by year
2025: 1 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 9 · 2016: 5 · 2015: 12 · 2014: 14 · 2013: 13 · 2012: 21
FWCI
12.87
Type
journal article
Language
en
Open access
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
Funders
National Institute on Drug Abuse (DA-3412, R01DA012447, DA12447)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
URB597, fatty acid amide hydrolase inhibitors, neuropathic pain, chronic constriction injury, endocannabinoid system, anandamide, CB1 receptor, CB2 receptor, rimonabant, SR144528, antihyperalgesia, oral administration, plasma drug concentration, analgesic drug development
MeSH terms
Fatty Acid Amide Hydrolases, Administration, Oral, Amidohydrolases, Analgesics, Animals, Benzamides, Capillary Permeability, Carbamates, Enzyme Inhibitors, Hyperalgesia, Male, Spinal Cord, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review